drugset / Trial / NCT00997945

10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

NCT00997945

Phase 1 Completed 15 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies.

Timeline

Start
2009-10
Primary completion
2010-09
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Zibotentan Small molecule 10 mg